The FDA has taken a major step toward approving Palforzia, a treatment for peanut allergy that may reduce both the number and severity of allergic reactions. The treatment, assuming it ultimately gets approval, would be for allergy sufferers ages 4 to 17 who have been diagnosed with peanut allergy. Palforzia is a biologic oral immunotherapy (OIT) that received Fast Track …